Overtreatment and Cost-Effectiveness of the See-and-Treat Strategy for Managing Cervical Precancer
Authors:
Open Access
- 1 May 2016
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 25 (5) , 807-814
Abstract
Background: See-and-treat using loop electrosurgical excision procedure (LEEP) has been recommended as an alternative in managing high-grade cervical squamous intraepithelial lesions, but existing literature lacks evidence of the strategy's cost-effectiveness. We evaluated the overtreatment and cost-effectiveness of the see-and-treat strategy compared with usual care. Methods: We modeled a hypothetical cohort of 40-year-old females who had not been screened for cervical cancer and followed them through their lifetimes using a Markov model. From a U.S. health-system perspective, the analysis was conducted in 2012 dollars and measured effectiveness in quality-adjusted life-years (QALY). We estimated incremental cost-effectiveness ratios (ICER) using a willingness-to-pay threshold of $50,000/QALY. The robustness of the see-and-treat strategy's cost-effectiveness and its overtreatment rates were further examined in various sensitivity analyses. Results: In the base-case, the see-and-treat strategy yielded an ICER of $70,774/QALY compared with usual care. For most scenarios in the deterministic sensitivity analysis, this strategy had ICERs larger than $50,000/QALY, and its cost-effectiveness was sensitive to the disutility of LEEP treatment and biopsy-directed treatment adherence under usual care. Probabilistic sensitivity analysis showed that the see-and-treat strategy had a 50.1% chance to be cost-effective. It had an average overtreatment rate of 7.1% and a 78.8% chance to have its overtreatment rate lower than the 10% threshold. Conclusion: The see-and-treat strategy induced an acceptable overtreatment rate. Its cost-effectiveness, compared with usual care, was indiscriminating at the chosen willingness-to-pay threshold but much improved when the threshold increased. Impact: The see-and-treat strategy was reasonable for particular settings, that is, those with low treatment adherence. Cancer Epidemiol Biomarkers Prev; 25(5); 807–14. ©2016 AACR.Keywords
Funding Information
- NCI NIH (P01 CA082710)
- NCI NIH (P30 CA006927)
- NCI NIH (R25 CA057712)
This publication has 33 references indexed in Scilit:
- Worldwide burden of cervical cancer in 2008Annals of Oncology, 2011
- Cervical cytology/histology discrepancy: a 4‐year review of patient outcomeCytopathology, 2010
- How Much Are Americans Willing to Pay for a Quality-Adjusted Life Year?Medical Care, 2008
- Accuracy of Colposcopy in the Diagnostic Setting Compared With the Screening SettingObstetrics & Gynecology, 2008
- Model for Assessing Human Papillomavirus Vaccination StrategiesEmerging Infectious Diseases, 2007
- See-and-treat strategy for diagnosis and management of cervical squamous intraepithelial lesionsThe Lancet Oncology, 2005
- Management choice and adherence to follow-up after colposcopy in women with cervical intraepithelial neoplasia 12001
- See-and-treat in the management of high-grade squamous intraepithelial lesions of the cervix: a resource utilization analysisObstetrics & Gynecology, 1999
- Cost-Effectiveness Analysis of Diagnosis and Management of Cervical Squamous Intraepithelial LesionsObstetrics & Gynecology, 1998
- The treatment of cervical intra-epithelial neoplasia: when could we ‘see and loop’European Journal of Obstetrics & Gynecology and Reproductive Biology, 1997